drugset / Trial / NCT00132756
Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer
Phase 1/2
Terminated
30 enrolled
Morton Plant Mease Health Care
Ortho Biotech Products, L.P. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug combination of Doxil (doxorubicin) and estramustine when used to treat prostate cancer that is resistant to hormones and to a chemotherapy type called taxanes. The primary hypothesis is to reduce the measurable disease or prostate-specific antigen (PSA) level by at least 50% from baseline.
Timeline
- Start
- 2003-12
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | estramustine | Other / unclassified | — | — |